Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including […]readmore
Tags : Voyager
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein […]readmore
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Shots: Voyager to receive $165M upfront including $115M in cash, $50M equity investment at $11.96/share and $1.7B milestones for its four gene therapy programs including VY-AADC & VY-FXN01. Additionally, Neurocrine […]readmore
Shots: Voyager’s program for Huntington’s Disease and Amyotrophic Lateral Sclerosis assessing VY-HTT01 at five wks. post-dosing in adult non-human primates & VY-SOD102 one-time intraparenchymal infusion after laminectomy The program demonstrated […]readmore